McDermott Advises Trizell on Development and Manufacturing Agreement with Catalent


Frankfurt, February 19, 2021 – McDermott Will & Emery advised Trizell GmbH on signing a development and manufacturing agreement with Catalent, an international pharmaceutical contract research and development company.

The agreement is to support the manufacturing of Trizell’s Phase 1 cell therapy for the treatment of micro- and macroangiopathies. It refers to the development of a manufacturing process and a subsequent supply of clinical material for a phase 1/2 clinical trial. The cell therapy product is to be manufactured at Catalent’s facility in Gosselies, Belgium.

Trizell GmbH, a subsidiary of Swiss-based Trizell Holding SA, is a German biotech company focusing on the research, development, production and distribution of innovative pharmaceutical and diagnostic products, primarily in the field of cell therapy.

Headquartered in New Jersey, Catalent is a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products.

Trizell GmbH was advised by McDermott’s Corprorate counsel Monika Emilia Richter.

About McDermott

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

Media Contacts